Protara Therapeutics Shares Slide 5.3% as Trading Volume Drops
Protara Therapeutics stock declined 5.3% on Wednesday to $2.48, with volume 61% below its average. Analysts remain mixed: seven rate the shares Buy and one rates them Sell, producing a Moderate Buy consensus and a $26.25 average target. The company recently reported a quarterly loss of $0.36 per share, missing estimates by $0.03, while institutional investors hold about 38.1% of the stock.
Protara Therapeutics, a clinical-stage biopharma developing cancer and rare-disease therapies, saw its shares last trade Wednesday at $2.48 after touching $2.47, down from a prior close of $2.62. Midday turnover was 701,413 shares, roughly 61% below the usual 1,806,964. Its 50-day and 200-day moving averages stood at $3.56 and $4.20.
The company's August 11 quarterly report showed a $0.36 per-share loss, $0.03 wider than expected. Seven analysts call the stock Buy and one Sell, yielding a Moderate Buy consensus and $26.25 average target. Institutions hold about 38.1%. Market value was $146.57 million; beta 1.47.
A decline in Protara's shares could affect current and prospective shareholders, employees, and partners tied to its clinical-stage programs. Lower trading volume and a wide gap between the market price and analyst target may signal uncertainty, potentially making future capital raising harder. If funding becomes constrained, development timelines for cancer and rare-disease therapies could slow, though such outcomes depend on many factors and are not certain.